In genetics, pathogenic means a change in a gene’s DNA sequence is capable of causing disease. When a lab report labels a variant as “pathogenic,” it’s saying there is strong evidence that this specific genetic change disrupts normal protein function in a way that leads to, or significantly raises the risk of, a health condition. It’s one of five categories labs use to classify genetic variants, and it sits at the most certain end of the scale.
The Five-Tier Classification System
Geneticists don’t simply call a variant “normal” or “abnormal.” Since 2015, clinical labs in the United States have followed a framework developed by the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology. This system sorts every variant into one of five categories: benign, likely benign, variant of uncertain significance (VUS), likely pathogenic, or pathogenic.
Benign means the change is harmless. Pathogenic means it causes or strongly predisposes someone to disease. The categories in between reflect decreasing levels of certainty. “Likely pathogenic” was defined to mean at least a 90% chance that the variant is disease-causing. A variant of uncertain significance, or VUS, is essentially a “maybe”: there isn’t enough evidence yet to say whether it’s harmful or harmless. Labs weigh multiple lines of evidence to place a variant in one of these categories, including how rare the change is in the general population, whether it’s been seen in people with the disease, and whether laboratory experiments show it disrupts the protein’s function.
How a Variant Gets Labeled Pathogenic
No single piece of evidence is usually enough. Labs combine different types of data, each carrying a different weight. A variant that completely knocks out a gene’s ability to produce a working protein carries very strong evidence of pathogenicity. A variant previously seen in unrelated people with the same disease adds strong evidence. Functional studies showing the variant breaks the protein in a lab dish contribute as well. Rarity in the general population provides moderate support, since a truly harmful variant tends not to spread widely. These pieces of evidence are combined using a structured scoring system, and only when the total weight crosses a defined threshold does the variant earn a “pathogenic” label.
This process is not static. A public database called ClinVar, maintained by the National Center for Biotechnology Information, collects classifications from labs and expert panels worldwide. When an expert panel reviews a variant, their classification takes priority over individual lab submissions. Variants can be reclassified over time as new evidence emerges, which is why a VUS today might become pathogenic (or benign) in the future.
What Pathogenic Variants Actually Do to Proteins
Most known disease-causing variants occur in the protein-coding regions of DNA, and they can break things in more than one way. The simplest mechanism is loss of function: the variant introduces a premature stop signal or destabilizes the protein’s shape so it can’t do its job. This is what happens with many variants in the CFTR gene that cause cystic fibrosis, where the protein responsible for moving chloride across cell membranes is absent or defective.
But loss of function is far from the only mechanism. Some pathogenic variants create a gain of function, where the protein becomes overactive or acquires a new, unwanted ability. Others act through a dominant-negative effect, where the faulty protein interferes with copies of the normal protein in the same cell. Still others change which molecules a protein binds to, increase its binding strength in harmful ways, trigger abnormal protein clumping, or create entirely new interactions that the cell was never designed to handle. Understanding the mechanism matters because it shapes how a disease behaves and, increasingly, which treatments might work.
BRCA Genes: A Well-Known Example
Pathogenic variants in the BRCA1 and BRCA2 genes are among the most widely recognized examples. These genes normally help repair damaged DNA. When one copy carries a pathogenic variant, the cell’s ability to fix DNA breaks is compromised, and cancer risk rises substantially.
More than 60% of women who inherit a pathogenic BRCA1 or BRCA2 variant will develop breast cancer during their lifetime. The risk of ovarian cancer reaches 39% to 58% for BRCA1 carriers and 13% to 29% for BRCA2 carriers. Prostate cancer risk is also elevated: 19% to 61% of men with a harmful BRCA2 change will develop prostate cancer by age 80. Pancreatic cancer, melanoma, and stomach cancer risks are increased as well, though to a lesser degree. People with these variants also tend to develop cancer at younger ages than the general population. Certain populations carry these variants at higher rates. About 2% of people of Ashkenazi Jewish descent have a pathogenic change in one of these two genes.
Pathogenic Doesn’t Always Mean Sick
One of the most important nuances is that carrying a pathogenic variant does not guarantee you will develop symptoms. This concept is called penetrance, which refers to the proportion of people with a given variant who actually develop the associated condition. Many pathogenic variants have reduced, or incomplete, penetrance.
BRCA variants illustrate this clearly. While the cancer risk is dramatically elevated compared to the general population, not every carrier develops cancer. Doctors cannot predict which carriers will be affected or when. The gap between carrying the variant and developing symptoms likely results from a combination of other genetic factors, environmental exposures, and lifestyle. This is why genetic test results describe risk, not destiny.
There’s also variable expressivity, which means that even among people who do develop symptoms, the severity and specific features of the condition can differ widely. Two family members with the same pathogenic variant might experience very different health outcomes.
Pathogenic vs. Variant of Uncertain Significance
If your genetic test comes back with a pathogenic result, that finding will directly shape your medical care. You’ll typically be referred to specialists, offered increased screening, and your close biological relatives may be encouraged to pursue their own testing since pathogenic variants often run in families. For cancer-related genes, a pathogenic result might lead to more frequent imaging, earlier screening, or preventive procedures.
A VUS is handled very differently. Professional guidelines state that a variant of uncertain significance should not be used in clinical decision-making. No additional surgeries, no increased screenings, no changes to your treatment plan. Acting on a VUS, such as pursuing a preventive mastectomy, could be unnecessary and potentially harmful if the variant is later reclassified as benign. The standard approach for a VUS is to wait and see. If the lab later reclassifies it based on new evidence, your genetic counselor will contact you with updated results and explain what the change means for you and your family.
What a Pathogenic Result Looks Like on Your Report
On a clinical genetic testing report, a pathogenic finding is typically listed as a “positive” result. The report will name the specific gene, describe the variant, and state its classification as pathogenic or likely pathogenic. Both classifications are treated similarly in clinical practice, since likely pathogenic still represents at least 90% certainty.
After receiving a positive result, you’ll generally meet with a genetic counselor who walks through what the finding means for your health, how it may change your medical management going forward, and what it could mean for your biological relatives. If the condition associated with the variant has specific symptoms or requires specialized care, you’ll be referred to doctors with experience in that area. The result is a starting point for a tailored care plan, not a diagnosis on its own.